- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05638776
Behandlung der chronisch obstruktiven Lungenerkrankung (COPD) mit pulmonaler Diffusionsstörung durch REGEND001
Eine multizentrische, randomisierte, einfach verblindete, Placebo-parallel-kontrollierte Forschung zum autologen Therapieprodukt REGEND001 zur Behandlung der chronisch obstruktiven Lungenerkrankung (COPD) mit pulmonaler Diffusionsstörung
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow. In a large number of patients, diffusion function is impaired along with the progression of disease. REGEND001 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, single-blind, placebo-parallel-controlled trial is performed to assess the efficacy and safety of REGEND001 cell therapy in treatment of chronic obstructive pulmonary disease with diffusion capacity defect.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China
- China-Japan Friendship Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China
- The Southwest Hospital of AMU
-
-
Guangdong
-
Guangzhou, Guangdong, China
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Xiangya Hospital of Central South University
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- The First Affiliated Hospital of Soochow University
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- The First Affiliated Hospital of Nanchang University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China
- Shanghai East Hospital
-
Shanghai, Shanghai Municipality, China
- Zhongshan Hospital affiliated to Fudan University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female, aged 40 to 75 at the time of signing informed consent.
- Diagnosed with COPD according to the 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD).
- The ratio of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)FEV1/FVC is < 70% after inhalation of bronchodilators.
- The diffusion function of carbon monoxide (DLCO) is ≥ 20% and < 80% of the predicted value at screening.
- Tolerated to pulmonary function tests.
- Tolerated to bronchoscopy
- Voluntary to sign the informed consent, coordinated to finish the trial-related procedures and tests, and capable of recording or stating the change of disease condition in a relatively complete manner.
Exclusion Criteria:
-
Females who are pregnant, nursing, or planning to be pregnant within a year after using this product (or males whose spouse planning to be pregnant);
-
Subjects with a positive result for any of the following tests at screening: treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody. But except the followings:
- Hepatitis B virus carriers (only HBsAg positive without any hepatitis symptom or sign, and all liver function tests present normal results or abnormal markers without clinical significance by the assessment of investigators);
- Cured hepatitis C patients (negative in HCV ribonucleic acid (RNA) test);
-
Subject with assessed survival time of < 1 year by investigators at screening;
-
Subject with malignant tumors or a history of malignant tumors at screening;
-
Subject with infections in lung or other sites, requiring intravenous drug treatment within a week prior to screening;
-
Subject with more than 4 moderate-to-severe AECOPD, resulting in hospitalization within a year prior to screening;
-
Subject with one or more pathogenetic or serologic findings of the novel coronavirus infection, or symptoms of suspected infection within 6 weeks prior to screening;
-
Subject with a history of invasive or noninvasive mechanical ventilation within 4 weeks prior to screening;
-
Subject who has taken prednisone tablets orally at a dose of ≥ 20 mg/day (or equivalent amount of other oral corticosteroids) within 4 weeks prior to screening;
-
Subject with major lung diseases other than COPD by assessment of investigators at screening;
-
Subject with severe systemic diseases other than lung within 6 months prior to screening and assessed to be inappropriate to participate in this trial by investigators;
-
Subject with severe anemia or poorly controlled granulocyte deficiency, thrombocytopenia by assessment of investigators;
-
Subject with abnormal coagulation and assessed to be negative for the safety of fiberoptic bronchoscopy operations at screening;
-
Subject requiring long-term anticoagulation therapy of using antiplatelet coagulant therapeutic agents and disable to discontinue their medications 1 week prior to cell collection and cell infusion as assessed by investigators;
-
Subject with a risk of suicide, a history of mental illness or a history of epilepsy at screening;
-
Subject with severe arrhythmias or heart conduction disorders (degree II or above) in 12-lead ECG test at screening;
-
Subject participated in other clinical trials with interventions within 3 months prior to screening;
-
Investigators, co-investigators, research coordinators, employees of research participants or research centers, or their family members;
-
Any circumstance considered to probably increase the risk of patients or interfere with the clinical trial.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
Placebo |
Transplantation of Placebo |
|
Experimental: REGEND001 cell therapy
REGEND001 cell therapy |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Responsive rate (RR)
Zeitfenster: 12 weeks after treatment, 24 weeks after treatment
|
Ratio of subjects responsive to the treatment. Subject is considered to be responsive to the treatment as (1) the lung diffusing capacity for carbon monoxide (DLCO) improvement meets MCID (minimal clinically important difference) at 12 or/and 24 weeks after therapy; and (2) mean of DLCO at 12 and 24 weeks is no less than the baseline value. MCID of DLCO improvement is 1.1 ml/min/mmHg (0.37 mmol·min -1·kPa-1) or 11% for measured value compared to baseline . |
12 weeks after treatment, 24 weeks after treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change of lung diffusing capacity for carbon monoxide (DLCO) from baseline
Zeitfenster: Within 52 weeks after treatment
|
DLCO is considered a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin. |
Within 52 weeks after treatment
|
|
Change of the alveolar volume (VA) from baseline
Zeitfenster: Winthin 52 weeks after treatment
|
Alveolar ventilation is the exchange of gas between the alveoli and the external environment. It is the process by which oxygen is brought into the lungs from the atmosphere and by which the carbon dioxide carried into the lungs in the mixed venous blood is expelled from the body. |
Winthin 52 weeks after treatment
|
|
Change of images of lung by high resolution computed tomography (HR-CT) from baseline
Zeitfenster: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
HR-CT images of lung will be analyzed to indicate the change of pulmonary structure. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of forced vital capacity (FVC) from baseline
Zeitfenster: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
FVC is the full amount of air that can be exhaled with effort in a complete breath. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of forced expiratory volume in one second (FEV1) from baseline
Zeitfenster: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
FEV1 is the volume of breath exhaled with effort in one second. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) from baseline
Zeitfenster: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
The FEV1/FVC is a ratio that reflects the amount of air you can forcefully exhale from your lungs. It's measured by spirometry, a test used to evaluate lung function. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of the diffusing capacity for carbon monoxide/ the alveolar volume (DLCO/VA) from baseline
Zeitfenster: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
The DLCO test refers to the diffusing capacity for carbon monoxide in the lungs. It's a type of pulmonary function test that helps to assess how well gas is exchanged between the lungs and the bloodstream.Since DLCO is affected by the amount of inhaled gas and lung volume, the subject's alveolar ventilation (VA) is also considered when evaluating diffusion function to exclude the effect of lung volume on diffusion volume. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of 6-minute-walk test (6MWT) from baseline
Zeitfenster: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
The 6MWT is a commonly used test for the objective assessment of functional exercise capacity by testing the distance patients can walk at the fastest speed within 6 minutes. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of modified medical research council (mMRC) dyspnea scale from baseline
Zeitfenster: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
It is a questionnaire to evaluate how breathlessness impacts daily activities. According to the degree of activity impacted by shortness of breath, mMRC results are divided into 0-4 grades. Grade 0 means no breathlessness except on strenuous exercise; grade 1 means shortness of breath when hurrying on the level or walking up a slight hill; grade 2 means walking slower than people of same age on the level because of breathlessness or having to stop to catch breath when walking at their own pace on the level; grade 3 means stoping for breath after walking ∼100 m or after few minutes on the level ground; and grade 4 means too breathless to leave the house, or breathless when dressing or undressing. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of chronic obstructive pulmonary disease Assessment Test (CAT) from baseline
Zeitfenster: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
The CAT is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time. The CAT scale includes a total of 8 items, 0~5 points for each item. The total score ranges 0~40 points. Score of 0-10 points indicates slight impact; Score of 11-20 points indicates medium impact: Score of 21-30 points indicates serious impact; Score of 31-40 points indicates very serious impact. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Annual frequency of exacerbations
Zeitfenster: 1 year after treatment
|
Frequency of exacerbations all through the year. A lower frequency means improvement of disease. |
1 year after treatment
|
|
Symptoms, physical examination
Zeitfenster: Baseline, treatment day (D1), 24 hours after treatment, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Number of cases with abnormal physical examination findings. |
Baseline, treatment day (D1), 24 hours after treatment, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
12-lead ECG
Zeitfenster: 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Number of cases with abnormal 12-lead Electrocardiogram (ECG). |
4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Blood routine
Zeitfenster: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Number of cases with abnormal laboratory test results. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Urine routine
Zeitfenster: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Number of cases with abnormal laboratory test results. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Blood biochemistry
Zeitfenster: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Number of cases with abnormal laboratory test results. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Function of blood clotting
Zeitfenster: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Number of cases with abnormal function of blood clotting. |
Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Carcinoembryonic antigen (CEA)
Zeitfenster: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
CEA is a tumor marker used for early diagnosis of lung cancer. |
Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Neuron-specific enolase (NSE)
Zeitfenster: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
NSE is a tumor marker significantly elevated in small cell lung cancer. |
Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Cytokeratin-19-fragment (CYFRA21-1)
Zeitfenster: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
CYFRA21-1 is a tumor marker which is valuable for the pathological classification and prognosis evaluation of lung cancer. |
Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Squamous cell carcinoma antigen (SCC)
Zeitfenster: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
SCC is a specific marker for lung squamous cell carcinoma.Tumor markers are monitored to assess the safety. |
Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- REGEND001-COPD-201
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .